• 1. Photochemical technologies assessed: the case of rose oxide
  Davide Ravelli,Stefano Protti,Paolo Neri,Maurizio Fagnoni,Angelo Albini Green Chem. 2011 13 1876
• 2. OLEDs as prospective light sources for microstructured photoreactors
  Dirk Ziegenbalg,Günter Kreisel,Dieter Wei?,Dana Kralisch Photochem. Photobiol. Sci. 2014 13 1005
• 3. Singlet oxygen oxidations in homogeneous continuous flow using a gas–liquid membrane reactor
  Antonia Kouridaki,Kevin Huvaere React. Chem. Eng. 2017 2 590
• 4. Monoterpenoids
  David H. Grayson Nat. Prod. Rep. 2000 17 385
• 5. Chiral porous organic frameworks and their application in enantioseparation
  Ying Zhang,Xiaoning Jin,Xiaofei Ma,Yong Wang Anal. Methods 2021 13 8

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxanes Oxanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxanes

Compound Introduction: CAS No 16409-43-1 and (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane

The compound identified by the chemical identifier CAS No 16409-43-1 corresponds to the enantiomerically pure form of (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane, a molecule of significant interest in the field of chiral chemistry and pharmaceutical research. This oxane derivative, characterized by its stereogenic center at the 4-position, has garnered attention due to its potential applications in drug development and catalysis.

The oxane ring, a five-membered heterocyclic structure containing one oxygen atom, is a common motif in biologically active compounds. Its flexibility and ability to adopt various conformations make it an attractive scaffold for designing molecules with specific interactions. In the case of (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane, the presence of a chiral center at the 4-position introduces asymmetry, which can influence both the physical properties and biological activity of the molecule.

Recent advancements in asymmetric synthesis have enabled the efficient preparation of enantiomerically pure oxane derivatives like (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane. These methods often employ transition metal-catalyzed reactions or biocatalytic approaches to achieve high enantiomeric excess. The ability to produce such compounds with high purity is crucial for pharmaceutical applications, where the stereochemistry of a molecule can significantly impact its efficacy and safety.

The structural features of (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane make it a promising candidate for further investigation in medicinal chemistry. The presence of a double bond in the 2-methylpropyl group and the methyl substituent at the 4-position contribute to its complex electronic environment. This complexity can be exploited to design molecules with tailored properties, such as improved solubility or enhanced binding affinity to biological targets.

In the context of drug discovery, oxane derivatives have been explored for their potential as pharmacophores in various therapeutic areas. For instance, modifications of the oxane ring have been shown to influence metabolic stability and oral bioavailability. The enantiomeric purity of (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane ensures that its biological effects can be studied without interference from its enantiomer, providing clearer insights into its mechanism of action.

Recent studies have highlighted the role of chiral oxanes in modulating enzyme activity. For example, derivatives of this class have been investigated for their interactions with enzymes involved in metabolic pathways relevant to diseases such as diabetes and cancer. The stereochemical configuration at the 4-position plays a critical role in determining how these molecules bind to their targets, making it a key focus for structural optimization.

The synthesis of complex molecules like (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane also contributes to the development of new synthetic methodologies. Techniques such as asymmetric hydrogenation and dynamic kinetic resolutions have been employed to achieve high yields and enantiomeric purity. These advancements not only facilitate access to valuable compounds but also expand the toolkit available for synthetic chemists.

From a broader perspective, the study of (4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane exemplifies the importance of interdisciplinary research in modern chemistry. By combining insights from organic synthesis, medicinal chemistry, and biochemistry, researchers can develop innovative solutions to complex problems. The continued exploration of chiral oxanes is likely to yield new therapeutic agents and deepen our understanding of molecular recognition processes.

The future directions for research on CAS No 16409-43-1 and its derivatives include further exploration of their biological activities and development into lead compounds for drug discovery. Additionally, computational studies using molecular modeling techniques can help predict how these molecules interact with biological targets, guiding experimental efforts towards more effective designs.

In conclusion, (4S)-4-methyl-2-(2-methylprop-1-en-1-yloxane) represents a fascinating example of how structural complexity can be harnessed for pharmaceutical applications. Its unique properties make it a valuable tool for researchers investigating chiral chemistry and drug development. As synthetic methods continue to improve, access to such compounds will become more efficient, paving the way for new discoveries in medicine.

• 4610-11-1(4-methyl-2-(2-methylprop-1-enyl)oxane)
• 101170-14-3(1,6-Octadiene, 3,7-dimethyl-3-(2-propenyloxy)-)
• 876-18-6(2H-Pyran, tetrahydro-4-methyl-2-(2-methyl-1-propenyl)-, trans-)
• 3033-23-6(2H-Pyran,tetrahydro-4-methyl-2-(2-methyl-1-propen-1-yl)-, (2S,4R)-)
• 60857-05-8(2H-Pyran,tetrahydro-4-methylene-2-(2-methyl-1-propen-1-yl)-)
• 62048-17-3(2H-1-Benzopyran, 3,4,4a,5,6,8a-hexahydro-4,7-dimethyl-)
• 5258-11-7((-)-TRANS-ROSE OXIDE)
• 131766-70-6(4-methyl-2-(2-methylprop-1-enyl)tetrahydropyran-4-ol)
• 876-17-5(rac-(2R,4S)-4-methyl-2-(2-methylprop-1-en-1-yl)oxane, cis)
• 113332-17-5(2H-Pyran, 2-ethenyltetrahydro-2,6-dimethyl-6-(4-methyl-3-penten-1-yl)-, (2R,6S)-rel-)